OBJECTIVES: The present study evaluated the prognostic implications of insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER)-2 in patients with colorectal cancer (CRC). METHODS: Our subjects were 91 patients who underwent surgery and subsequently received fluoropyrimidines. Expressions of IGF-1R, EGFR and HER-2 in primary lesions were analyzed immunohistochemically to determine the prognostic significance of these biomarkers. RESULTS: Overexpression was found for IGF-1R in 48 tumors (53%), EGFR in 57 (63%) and HER-2 in 2 (2%). Overexpression of IGF-1R was significantly correlated with shorter survival from the start of first-line chemotherapy (p = 0.033). Overexpression of EGFR was a significant predictor of clinical response to fluoropyrimidines (p = 0.032). Multivariate analysis of potential prognostic factors showed that IGF-1R expression and worsened performance status were independent predictors of poor outcomes. CONCLUSIONS: Our results suggest that anti-IGF-1R strategies may offer a useful approach in molecular therapy for CRC, which has the potential to improve outcomes.
OBJECTIVES: The present study evaluated the prognostic implications of insulin-like growth factor-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR) and humanepidermal growth factor receptor (HER)-2 in patients with colorectal cancer (CRC). METHODS: Our subjects were 91 patients who underwent surgery and subsequently received fluoropyrimidines. Expressions of IGF-1R, EGFR and HER-2 in primary lesions were analyzed immunohistochemically to determine the prognostic significance of these biomarkers. RESULTS: Overexpression was found for IGF-1R in 48 tumors (53%), EGFR in 57 (63%) and HER-2 in 2 (2%). Overexpression of IGF-1R was significantly correlated with shorter survival from the start of first-line chemotherapy (p = 0.033). Overexpression of EGFR was a significant predictor of clinical response to fluoropyrimidines (p = 0.032). Multivariate analysis of potential prognostic factors showed that IGF-1R expression and worsened performance status were independent predictors of poor outcomes. CONCLUSIONS: Our results suggest that anti-IGF-1R strategies may offer a useful approach in molecular therapy for CRC, which has the potential to improve outcomes.
Authors: Jianying Dong; Arlene Sereno; Dikran Aivazian; Emma Langley; Brian R Miller; William B Snyder; Eric Chan; Matt Cantele; Ronald Morena; Ingrid B J K Joseph; Antonio Boccia; Cyrus Virata; James Gamez; Grace Yco; Michael Favis; Xiufeng Wu; Christilyn P Graff; Qin Wang; Ellen Rohde; Rachel Rennard; Lisa Berquist; Flora Huang; Ying Zhang; Sharon X Gao; Steffan N Ho; Stephen J Demarest; Mitchell E Reff; Kandasamy Hariharan; Scott M Glaser Journal: MAbs Date: 2011-05-01 Impact factor: 5.857
Authors: Joseph A Ludwig; Salah-Eddine Lamhamedi-Cherradi; Ho-Young Lee; Aung Naing; Robert Benjamin Journal: Cancers (Basel) Date: 2011-07-26 Impact factor: 6.639